سعر لورنوكس 4 مجم 10 أقراص 2022

Lornox 4mg 10 f.c. tabs by EGPI (Egypt): lornoxicam 4 mg film-coated tablets, an oxicam NSAID with analgesic and anti-inflammatory effects.

• About 20% of patients treated with lornoxicam can be expected to experience adverse reactions; common ones are nausea, abdominal pain, dyspepsia, diarrhoea and vomiting. Oedema, hypertension and cardiac failure have been reported with NSAIDs.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland

• Contraindicated with: hypersensitivity to lornoxicam or excipients; thrombocytopenia; hypersensitivity (asthma, rhinitis, angioedema or urticaria) to other NSAIDs including acetylsalicylic acid; severe heart failure; gastrointestinal, cerebrovascular or other bleeding disorders; history of NSAID-related GI bleeding or perforation; active or recurrent peptic ulcer/haemorrhage; severe hepatic impairment; severe renal impairment; third trimester of pregnancy.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland

• NSAID class warnings: gastrointestinal bleeding, ulceration and perforation (higher risk at higher doses, in the elderly and with ulcer history; consider gastroprotection); cardiovascular thrombotic risk, fluid retention and oedema; serious skin reactions (SJS/TEN); may precipitate bronchospasm in asthma; inhibits platelet aggregation; monitor blood counts, liver and renal function in long-term use; may impair fertility.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland

• Anticoagulants (warfarin, phenprocoumon, heparin)Increased bleeding risk; NSAIDs may enhance the effect of anticoagulants; monitor INR.Health Products Regulatory Authority (HPRA), Ireland
• ACE inhibitors, angiotensin II receptor antagonists, diuretics, beta-blockersReduced antihypertensive/diuretic effect and increased risk of acute renal impairment, especially in dehydrated or elderly patients.Health Products Regulatory Authority (HPRA), Ireland
• Corticosteroids, SSRIs, antiplatelet agents (including aspirin)Increased risk of gastrointestinal ulceration or bleeding.Health Products Regulatory Authority (HPRA), Ireland
• Methotrexate, lithium, ciclosporin, tacrolimus, digoxinLornoxicam may raise levels or toxicity of these drugs (methotrexate, lithium, digoxin) or increase nephrotoxicity (ciclosporin, tacrolimus).Health Products Regulatory Authority (HPRA), Ireland
• Cimetidine; CYP2C9 inhibitors or inducersCimetidine increases lornoxicam plasma levels; lornoxicam is metabolised by CYP2C9, so inhibitors/inducers may change exposure.Health Products Regulatory Authority (HPRA), Ireland
• Sulphonylureas; quinolone antibiotics; pemetrexedPossible increased hypoglycaemic effect (sulphonylureas), increased risk of seizures (quinolones) and reduced pemetrexed clearance.Health Products Regulatory Authority (HPRA), Ireland

• No data on excretion in human milk; lornoxicam is excreted in the milk of lactating rats in relatively high concentrations, so it should not be used in breastfeeding women.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland

• Lornoxicam: Oxicam NSAID with analgesic properties; acts mainly by inhibiting cyclooxygenase and prostaglandin synthesis, desensitising peripheral nociceptors and inhibiting inflammation.